Research on Genetic Factors Influencing Sickle Cell Disease and Thalassemia in Children and Adults
Led by Cyprus Institute of Neurology and Genetics · Updated on 2024-03-20
30000
Participants Needed
26
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying genetic modifiers in hemoglobinopathies, including sickle cell disease and beta-thalassemia, through a large-scale, multi-ethnic genome-wide association study GWAS. These diseases vary widely in severity, influenced partly by genetic factors. The study aims to discover new genetic modifiers, validate known ones, pool existing genomic data, standardize disease descriptions, create a comprehensive research resource, and develop risk scores to help stratify patients based on disease severity and treatment response.
The study will collect blood samples during routine clinical visits to perform GWAS experiments on individuals with hemoglobinopathies. Participants include those with various genotypes of sickle cell disease, beta-thalassemia, and alpha-thalassemia, without restrictions on gender or ethnicity. All participants will provide consent, and DNA samples may be collected if not already available in existing biobanks.
Participants will contribute data including genetic, phenotypic, and functional information. The study will analyze worldwide patient demographics, genotypes, and disease severity. Researchers will investigate genetic modifiers related to survival, neurological function, renal impairment, pain syndromes, pulmonary hypertension, and treatment responses. This observational study involves data collection over five years, with no investigational treatments administered.
CONDITIONS
Brief Title
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Research Team
P
Petros Kountouris, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Clinical diagnosis of inherited hemoglobinopathy including sickle cell disease, beta-thalassemia, or alpha-thalassemia, any genotype
Age 2 years or older at the time of phenotypic data collection
No restrictions on gender, ethnicity, or other medical conditions
You will not qualify if you...
Patients who have received stem cell transplantation or genetic therapy
Age under 2 years at the time of phenotypic data collection
Patient or legal representative unwilling or unable to give consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) during routine clinical care
Diagnostic Evaluation
Duration - Up to 5 years
Participants provide blood samples during routine clinical visits for genetic analysis using GWAS to identify genetic modifiers of hemoglobinopathies.
Blood samples collected during routine clinical visits as needed
Long-term Monitoring
Duration - Up to 5 years
Participants are observed over time to collect phenotypic data and monitor clinical outcomes related to hemoglobinopathies.
Phenotypic data collected during routine healthcare visits
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Long-Term Follow-Up Study for Patients With Hemoglobinopathy Treated with BEAM-101
Observing Safety and Outcomes for Up to 15 Years After Treatment
Phase 1b Open-Label Study Evaluating Safety and Effects of DISC-3405 in Adults With Sickle Cell Disease
Evaluating Etavopivat for Brain Blood Flow in Children 12-16 Years with Sickle Cell Disease at Risk of Stroke
Study of Osivelotor Compared to Placebo in Adults and Adolescents with Sickle Cell Disease Evaluating Safety and Effectiveness
Evaluation of ITU512 Safety, Pharmacokinetics, and Effects in Healthy Adults and Sickle Cell Disease Patients
A Pilot Study Using MRI and Optical Techniques to Monitor Brain Oxygen and Blood Flow in Children with Sickle Cell Disease Ages 8 to 18
Long-term Open-label Study Evaluating Safety and Efficacy of Etavopivat in Adults and Children with Sickle Cell Disease or Thalassaemia After Prior Treatment
Immune Suppression Treatment Before Haploidentical Hematopoietic Cell Transplantation for Children and Adults With Severe Sickle Cell Disease or Beta-Thalassemia
Evaluating Nicotinamide and Oral Tetrahydrouridine-Decitabine Combination Treatment for High-Risk Sickle Cell Disease
Global Phase 3 Study of Oral Etavopivat Versus Placebo to Treat Adolescents and Adults with Sickle Cell Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies.